Biotechmaster
27.01.2011, 09:29
Diese Aktie hat locker 5 Bagger Potential WENN die Phase 3ergebnisse gut ausfallen .Also wer geren etwas riskiert sollte hier zuschlagen .
Antisoma (ASM.L)
Marktkap: 37 Mil
Cash: 32 Mil
AS1413 phase III data in secondary AML expected Q1 2011
Antisoma announced this week that it expects results from the ACCEDE phase III trial of AS1413 in secondary acute myeloid leukaemia (secondary AML) during the first quarter of 2011.
Secondary AML represents a significant fraction of AML cases. This form of the disease evolves from myelodysplastic syndrome (MDS) or results from chemotherapy or radiotherapy treatment for other cancers. Patients respond particularly poorly to current AML therapies.
Antisoma’s ACCEDE trial compares a novel regimen of AS1413 plus cytarabine with a standard regimen of daunorubicin and cytarabine. Enrolment of over 420 patients was completed in September. If the trial yields positive data, Antisoma plans to file for marketing authorisations.
Antisoma (ASM.L)
Marktkap: 37 Mil
Cash: 32 Mil
AS1413 phase III data in secondary AML expected Q1 2011
Antisoma announced this week that it expects results from the ACCEDE phase III trial of AS1413 in secondary acute myeloid leukaemia (secondary AML) during the first quarter of 2011.
Secondary AML represents a significant fraction of AML cases. This form of the disease evolves from myelodysplastic syndrome (MDS) or results from chemotherapy or radiotherapy treatment for other cancers. Patients respond particularly poorly to current AML therapies.
Antisoma’s ACCEDE trial compares a novel regimen of AS1413 plus cytarabine with a standard regimen of daunorubicin and cytarabine. Enrolment of over 420 patients was completed in September. If the trial yields positive data, Antisoma plans to file for marketing authorisations.